Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. Jul 27, 2014; 6(7): 520-526
Published online Jul 27, 2014. doi: 10.4254/wjh.v6.i7.520
Published online Jul 27, 2014. doi: 10.4254/wjh.v6.i7.520
Table 3 Percentage of patients who responded in terms of rapid virologic response, early virologic response, end of treatment virologic response, and sustained virologic response in genotypes 1, 3 and 4 by per protocol analysis
Parameter | Genotype 1 | Genotype 31 | Genotype 4 |
(n/N) | (n/N) | (n/N) | |
RVR | 25.9% (7/27) | 74.1% (40/54) | 58.8% (10/17) |
EVR | 74.1% (20/27) | 100% (49/49) | 88.2% (15/17) |
ETVR | 84.2% (16/19) | 89.8% (44/49) | 75.0% (12/16) |
SVR | 60.0% (12/20) | 76.6% (36/47) | 60.0% (9/15) |
- Citation: Rao P, Koshy A, Philip J, Premaletha N, Varghese J, Narayanasamy K, Mohindra S, Pai NV, Agarwal MK, Konar A, Vora HB. Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C. World J Hepatol 2014; 6(7): 520-526
- URL: https://www.wjgnet.com/1948-5182/full/v6/i7/520.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i7.520